Adaptive Biotechnologies Upsizes Convertible Notes Offering to $300M, Prices at 40% Premium
ADPT sits 72% above its 52-week low of $9.955 on elevated volume (3.4× avg).
Summary
Adaptive Biotechnologies priced an upsized $300 million offering of 0% convertible senior notes due 2031, an increase from the previously announced $250 million. This follows the proposed offering announcement on June 15th. The offering provides approximately $290.8 million in net proceeds, significantly boosting the company's capital. The notes have a favorable 0% interest rate and an initial conversion price of $24.11, representing a 40% premium over the prior day's closing price, which limits immediate dilutive pressure. The company also plans to repurchase $25 million worth of its common stock concurrently, further mitigating dilution. Proceeds will be used for debt repayment, general corporate purposes, and initiatives in the MRD business. The offering is scheduled to settle on June 22, 2026.
At the time of this announcement, ADPT was trading at $17.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $9.96 to $20.76. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.